Desmoplastic small round cell tumor: report of 2 cases treated with chemotherapy alone or in combination with bevacizumab.
Here, we present 2 case reports of patients with desmoplastic small round cell tumor (DSRCT), a very rare and aggressive mesenchymal cancer, and we discuss 2therapeutic options for this sarcoma. This report focuses on men aged 22 and 37 years, respectively. The first patient presented with an abdominopelvic mass which was not suitable for surgery. He underwent chemotherapy (adriblastina and cisplatin) with a brief partial remission and survival time of 13 months. The second patient presented with an abdominal mass and underwent partial resection. He received chemotherapy and bevacizumab, resulting in a partial remission and a survival time of 34 months. The extent of surgery and monoclonal antibody use probably had a positive impact on survival. It is necessary to include specific targeted therapies in an attempt to improve survival. Surprisingly, positron emission tomography was not effective in restaging of the second patient, emphasizing the importance of computed tomography or magnetic resonance in DSRCT.
Department of Oncology, Federal University of Uberlândia, Uberlândia, Brazil.
Rogério Agenor
RA
de Araújo
School of Medicine, Federal University of Uberlândia, Uberlândia, Brazil.
Breno Jeha
BJ
Araújo
Abdominal tumor; Bevacizumab; Chemotherapy; Desmoplastic small round cell tumor